Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma

被引：30

作者：

Bernasconi, Elena ^{[1
]}

Gaudio, Eugenio ^{[1
]}

Lejeune, Pascale ^{[2
]}

Tarantelli, Chiara ^{[1
]}

Cascione, Luciano ^{[1
,3
]}

Kwee, Ivo ^{[1
,4
,5
]}

Spriano, Filippo ^{[1
]}

Rinaldi, Andrea ^{[1
]}

Mensah, Afua A. ^{[1
]}

Chung, Elaine ^{[1
]}

Stathis, Anastasios ^{[3
]}

Siegel, Stephan ^{[2
]}

Schmees, Norbert ^{[2
]}

Ocker, Matthias ^{[3
]}

Zucca, Emanuele ^{[4
]}

Haendler, Bernard ^{[2
]}

Bertoni, Francesco ^{[1
,3
]}

机构：

[1] USI, IOR, Bellinzona, Switzerland

[2] Bayer AG, Drug Discovery, Berlin, Germany

[3] Oncol Inst Southern Switzerland IOSI, Bellinzona, Switzerland

[4] IDSIA Dalle Molle Inst Artificial Intelligence, Manno, Switzerland

[5] SIB, Lausanne, Switzerland

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2017年 / 178卷 / 06期

关键词：

Lymphomas; BET Bromodomain; Epigenetics; EZH2; ibrutinib; mTOR; B-CELL LYMPHOMA; THERAPEUTIC STRATEGY; ANTITUMOR-ACTIVITY; TARGETING MYCN; COMBINATION; MODELS; CANCER; APOPTOSIS; EFFICACY; GENES;

D O I：

10.1111/bjh.14803

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The epigenome is often deregulated in cancer and treatment with inhibitors of bromodomain and extra-terminal proteins, the readers of epigenetic acetylation marks, represents a novel therapeutic approach. Here, we have characterized the anti-tumour activity of the novel bromodomain and extra-terminal (BET) inhibitor BAY 1238097 in preclinical lymphoma models. BAY 1238097 showed anti-proliferative activity in a large panel of lymphoma-derived cell lines, with a median 50% inhibitory concentration between 70 and 208 nmol/l. The compound showed strong anti-tumour efficacy in vivo as a single agent in two diffuse large B cell lymphoma models. Gene expression profiling showed BAY 1238097 targeted the NFKB/TLR/JAK/STAT signalling pathways, MYC and E2F1-regulated genes, cell cycle regulation and chromatin structure. The gene expression profiling signatures also highly overlapped with the signatures obtained with other BET Bromodomain inhibitors and partially overlapped with HDAC-inhibitors, mTOR inhibitors and demethylating agents. Notably, BAY 1238097 presented in vitro synergism with EZH2, mTOR and BTK inhibitors. In conclusion, the BET inhibitor BAY 1238097 presented promising anti-lymphoma preclinical activity in vitro and in vivo, mediated by the interference with biological processes driving the lymphoma cells. Our data also indicate the use of combination schemes targeting EZH2, mTOR and BTK alongside BET bromodomains.

引用

页码：936 / 948

页数：13

共 45 条

[1] Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study [J].

Amorim, Sandy ;

Stathis, Anastasios ;

Gleeson, Mary ;

Iyengar, Sunil ;

Magarotto, Valeria ;

Leleu, Xavier ;

Morschhauser, Franck ;

Karlin, Lionel ;

Broussais, Florence ;

Rezai, Keyvan ;

Herait, Patrice ;

Kahatt, Carmen ;

Lokiec, Francois ;

Salles, Gilles ;

Facon, Thierry ;

Palumbo, Antonio ;

Cunningham, David ;

Zucca, Emanuele ;

Thieblemont, Catherine .

LANCET HAEMATOLOGY, 2016, 3 (04) :E196-E204

[2] Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study [J].

Berthon, Celine ;

Raffoux, Emmanuel ;

Thomas, Xavier ;

Vey, Norbert ;

Gomez-Roca, Carlos ;

Yee, Karen ;

Taussig, David Christopher ;

Rezai, Keyvan ;

Roumier, Christophe ;

Herait, Patrice ;

Kahatt, Carmen ;

Quesnel, Bruno ;

Michallet, Mauricette ;

Recher, Christian ;

Lokiec, Francois ;

Preudhomme, Claude ;

Dombret, Herve .

LANCET HAEMATOLOGY, 2016, 3 (04) :E186-E195

[3] BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma [J].

Bhadury, Joydeep ;

Nilsson, Lisa M. ;

Muralidharan, Somsundar Veppil ;

Green, Lydia C. ;

Li, Zhoulei ;

Gesner, Emily M. ;

Hansen, Henrik C. ;

Keller, Ulrich B. ;

McLure, Kevin G. ;

Nilsson, Jonas A. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (26) :E2721-E2730

[4] Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes [J].

Boi, Michela ;

Todaro, Maria ;

Vurchio, Valentina ;

Yang, Shao Ning ;

Moon, John ;

Kwee, Ivo ;

Rinaldi, Andrea ;

Pan, Heng ;

Crescenzo, Ramona ;

Cheng, Mangeng ;

Cerchietti, Leandro ;

Elemento, Olivier ;

Riveiro, Maria E. ;

Cvitkovic, Esteban ;

Bertoni, Francesco ;

Inghirami, Giorgio .

ONCOTARGET, 2016, 7 (48) :79623-79639

[5] The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs [J].

Boi, Michela ;

Gaudio, Eugenio ;

Bonetti, Paola ;

Kwee, Ivo ;

Bernasconi, Elena ;

Tarantelli, Chiara ;

Rinaldi, Andrea ;

Testoni, Monica ;

Cascione, Luciano ;

Ponzoni, Maurilio ;

Mensah, Afua Adjeiwaa ;

Stathis, Anastasios ;

Stussi, Georg ;

Riveiro, Maria Eugenia ;

Herait, Patrice ;

Inghirami, Giorgio ;

Cvitkovic, Esteban ;

Zucca, Emanuele ;

Bertoni, Francesco .

CLINICAL CANCER RESEARCH, 2015, 21 (07) :1628-1638

[6] PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma [J].

Boi, Michela ;

Rinaldi, Andrea ;

Kwee, Ivo ;

Bonetti, Paola ;

Todaro, Maria ;

Tabbo, Fabrizio ;

Piva, Roberto ;

Rancoita, Paola M. V. ;

Matolcsy, Andras ;

Timar, Botond ;

Tousseyn, Thomas ;

Maria Rodriguez-Pinilla, Socorro ;

Piris, Miguel A. ;

Bea, Silvia ;

Campo, Elias ;

Bhagat, Govind ;

Swerdlow, Steven H. ;

Rosenwald, Andreas ;

Ponzoni, Maurilio ;

Young, Ken H. ;

Piccaluga, Pier Paolo ;

Dummer, Reinhard ;

Pileri, Stefano ;

Zucca, Emanuele ;

Inghirami, Giorgio ;

Bertoni, Francesco .

BLOOD, 2013, 122 (15) :2683-2693

[7] Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors [J].

Ceribelli, Michele ;

Kelly, Priscilla N. ;

Shaffer, Arthur L. ;

Wright, George W. ;

Xiao, Wenming ;

Yang, Yibin ;

Griner, Lesley A. Mathews ;

Guha, Rajarshi ;

Shinn, Paul ;

Keller, Jonathan M. ;

Liu, Dongbo ;

Patel, Paresma R. ;

Ferrer, Marc ;

Joshi, Shivangi ;

Nerle, Sujata ;

Sandy, Peter ;

Normant, Emmanuel ;

Thomas, Craig J. ;

Staudt, Louis M. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (31) :11365-11370

[8] Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma [J].

Chapuy, Bjoern ;

McKeown, Michael R. ;

Lin, Charles Y. ;

Monti, Stefano ;

Roemer, Margaretha G. M. ;

Qi, Jun ;

Rahl, Peter B. ;

Sun, Heather H. ;

Yeda, Kelly T. ;

Doench, John G. ;

Reichert, Elaine ;

Kung, Andrew L. ;

Rodig, Scott J. ;

Young, Richard A. ;

Shipp, Margaret A. ;

Bradner, James E. .

CANCER CELL, 2013, 24 (06) :777-790

[9] Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method [J].

Chou, Ting-Chao .

CANCER RESEARCH, 2010, 70 (02) :440-446

[10]

Dalla Favera R., 2017, HEMATOL ONCOL, V35, P74

← 1 2 3 4 5 →